← Back

Wire · opportunities

Will the first approved psychedelic become a blockbuster?

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharmavoice.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Compass Pathways and Usona Institute are competing to be the first to gain FDA approval for a psilocybin-based treatment for depression. Usona's faster FDA review and potential ahead-of-Compass filing creates uncertainty over who will dominate the emerging psychedelic treatment market.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 21 Oct 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You should watch Usona closely as their surprise fast track FDA filing pressure Compass to move faster or lose the lead in approved psychedelic depression treatments. Pricing and payer coverage will decide if you can turn approval into market success.

◆ Coverage

5 sources · first reported 21 Oct 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

BiotechpsychedelicsFDA-approvaldepression-treatmentpsilocybindrug-development